Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors
Recent advances in histone deacetylase targeted cancer therapy
Lactate, a product of glycolytic metabolism, inhibits histone deacetylase activity and promotes changes in gene expression